{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T04:12:41Z","timestamp":1750824761300,"version":"3.41.0"},"reference-count":22,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2017,8,14]],"date-time":"2017-08-14T00:00:00Z","timestamp":1502668800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2017,8,14]],"date-time":"2017-08-14T00:00:00Z","timestamp":1502668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Dong-A ST Co., Ltd., Seoul, Korea"},{"name":"Global Center of Excellence in Clinical Trials","award":["HI14C1062"],"award-info":[{"award-number":["HI14C1062"]}]},{"name":"Ministry of Health and Welfare, Korea"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pharm Ther"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1111\/jcpt.12604","type":"journal-article","created":{"date-parts":[[2017,8,14]],"date-time":"2017-08-14T20:02:37Z","timestamp":1502740957000},"page":"689-694","source":"Crossref","is-referenced-by-count":7,"title":["Effects of clarithromycin on the pharmacokinetics of evogliptin in healthy volunteers"],"prefix":"10.1155","volume":"42","author":[{"given":"E. S.","family":"Oh","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Medicine and Regulatory Sciences; Colleges of Medicine and Pharmacy; Yonsei University; Incheon Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Pediatrics; Severance Hospital; Yonsei University College of Medicine; Seoul Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. O.","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Pediatrics; Severance Hospital; Yonsei University College of Medicine; Seoul Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. H.","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Medicine and Regulatory Sciences; Colleges of Medicine and Pharmacy; Yonsei University; Incheon Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y. N.","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Pediatrics; Severance Hospital; Yonsei University College of Medicine; Seoul Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. J.","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Clinical Development; Dong-A ST Co., Ltd.; Seoul Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. S.","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Medicine and Regulatory Sciences; Colleges of Medicine and Pharmacy; Yonsei University; Incheon Korea"},{"name":"Department of Clinical Pharmacology and Pediatrics; Severance Hospital; Yonsei University College of Medicine; Seoul Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,8,14]]},"reference":[{"key":"10.1111\/jcpt.12604-BIB0001|jcpt12604-cit-0001","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2337\/diaclin.33.2.97","article-title":"Standards of medical care in diabetes-2015 abridged for primary care providers","volume":"33","author":"American Diabetes Association","year":"2015","journal-title":"Clin Diabetes"},{"key":"10.1111\/jcpt.12604-BIB0002|jcpt12604-cit-0002","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.2337\/dc12-1609","article-title":"Relationships between gastric emptying, postprandial glycemia, and incretin hormones","volume":"36","author":"Marathe","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1111\/jcpt.12604-BIB0003|jcpt12604-cit-0003","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.bbapap.2005.05.010","article-title":"Type 2 diabetes-therapy with dipeptidyl peptidase IV inhibitors","volume":"1751","author":"Demuth","year":"2005","journal-title":"Biochim Biophys Acta"},{"key":"10.1111\/jcpt.12604-BIB0004|jcpt12604-cit-0004","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.lfs.2011.10.007","article-title":"DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes","volume":"90","author":"Kim","year":"2012","journal-title":"Life Sci"},{"key":"10.1111\/jcpt.12604-BIB0005|jcpt12604-cit-0005","unstructured":"FDA Guidance for industry: drug interaction studies -study design, data analysis, implications for dosing, and labeling recommendations 2012"},{"key":"10.1111\/jcpt.12604-BIB0006|jcpt12604-cit-0006","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0090-9556(24)15182-3","article-title":"An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation","volume":"28","author":"Mayhew","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/jcpt.12604-BIB0007|jcpt12604-cit-0007","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1124\/dmd.110.032177","article-title":"Confidence assessment of the Simcyp time-based approach and a static mathematical model in predicting clinical drug-drug interactions for mechanism-based CYP3A inhibitors","volume":"38","author":"Wang","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/jcpt.12604-BIB0008|jcpt12604-cit-0008","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2174\/138920008784746382","article-title":"Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions","volume":"9","author":"Yang","year":"2008","journal-title":"Curr Drug Metab"},{"key":"10.1111\/jcpt.12604-BIB0009|jcpt12604-cit-0009","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1128\/AAC.00532-07","article-title":"Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis","volume":"51","author":"Traunmuller","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/jcpt.12604-BIB0010|jcpt12604-cit-0010","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1172\/JCI113156","article-title":"Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man","volume":"80","author":"Watkins","year":"1987","journal-title":"J Clin Invest"},{"key":"10.1111\/jcpt.12604-BIB0011|jcpt12604-cit-0011","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1172\/JCI116064","article-title":"Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes","volume":"90","author":"Kolars","year":"1992","journal-title":"J Clin Invest"},{"key":"10.1111\/jcpt.12604-BIB0012|jcpt12604-cit-0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10408449209145319","article-title":"The human hepatic cytochromes P450 involved in drug metabolism","volume":"22","author":"Wrighton","year":"1992","journal-title":"Crit Rev Toxicol"},{"key":"10.1111\/jcpt.12604-BIB0013|jcpt12604-cit-0013","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.clpt.2004.10.002","article-title":"Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4\/5 activity and expression","volume":"77","author":"Pinto","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/jcpt.12604-BIB0014|jcpt12604-cit-0014","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0009-9236(98)90146-1","article-title":"The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin","volume":"64","author":"Gorski","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/jcpt.12604-BIB0015|jcpt12604-cit-0015","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/jnci\/92.16.1295","article-title":"A family of drug transporters: the multidrug resistance-associated proteins","volume":"92","author":"Borst","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/jcpt.12604-BIB0016|jcpt12604-cit-0016","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/mc.2940130302","article-title":"Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy","volume":"13","author":"Wacher","year":"1995","journal-title":"Mol Carcinog"},{"key":"10.1111\/jcpt.12604-BIB0017|jcpt12604-cit-0017","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1185\/030079907X178766","article-title":"Oral antidiabetic agents in type 2 diabetes","volume":"23","author":"Levetan","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/jcpt.12604-BIB0018|jcpt12604-cit-0018","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jama.298.2.194","article-title":"Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis","volume":"298","author":"Amori","year":"2007","journal-title":"JAMA"},{"key":"10.1111\/jcpt.12604-BIB0019|jcpt12604-cit-0019","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/j.1463-1326.2012.01610.x","article-title":"Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis","volume":"14","author":"Goossen","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1111\/jcpt.12604-BIB0020|jcpt12604-cit-0020","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1177\/0192623313516828","article-title":"Vascular origin of vildagliptin-induced skin effects in Cynomolgus monkeys: pathomechanistic role of peripheral sympathetic system and neuropeptide Y","volume":"42","author":"Hoffmann","year":"2014","journal-title":"Toxicol Pathol"},{"key":"10.1111\/jcpt.12604-BIB0021|jcpt12604-cit-0021","unstructured":"Prescribing information -Onglyza AstraZeneca Pharmaceuticals LP 2009"},{"key":"10.1111\/jcpt.12604-BIB0022|jcpt12604-cit-0022","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.2147\/DDDT.S65678","article-title":"Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers","volume":"8","author":"Gu","year":"2014","journal-title":"Drug Des Devel Ther"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12604","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jcpt.12604\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T22:49:01Z","timestamp":1750805341000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.12604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,14]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"URL":"https:\/\/doi.org\/10.1111\/jcpt.12604","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"type":"print","value":"0269-4727"}],"subject":[],"published":{"date-parts":[[2017,8,14]]}}}